New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused ...

Researchers assessed the safety and efficacy of the novel PolaR-ICE regimen among patients with relapsed or refractory DLBCL in the second-line setting.

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a ...

Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...

The TGA registration establishes Minjuvi as the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for this group of patients. 2 ...

Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required ...

Legend, like Kelonia, develops and manufactures cell therapies to treat life-threatening diseases, particularly cancer. ・Legend is best known for Carvykti, a CAR-T treatment for relapsed or refractory ...

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in R/R High-Risk Myelodysplastic Syndrome & R/R Acute Myeloid Leukemia ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...